New sickle cell gene therapies are a breakthrough, but solving how to pay their high prices is a struggle

Breakthrough sickle cell treatments are available in the U.S., but their high cost is forcing insurers to get creative.

Previous post Here’s why Citi analysts think banks will avoid commercial-real-estate losses
Next post To save Social Security, they may come for your 401(k)